Seasonal Influenza Vaccines – Forecast in Asia-Pacific Markets to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Seasonal influenza is a viral infection that occurs annually in the winter months from December to March/April in the Northern Hemisphere and from May to August/September in the Southern Hemisphere, though most of India follows Southern Hemisphere seasonality Two types of influenza virus, type A and B, are responsible for the majority of seasonal influenza infections in humans, and due to frequent virus mutations annual vaccination is recommended. The WHO estimates three to five million cases of severe seasonal influenza infections and 290,000 to 650,000 influenza-related respiratory deaths, most of them in the elderly population. Therefore, many countries recommend annual immunization against seasonal influenza, especially for high-risk groups such as young children, pregnant women, elderly people, and people with chronic diseases, but seasonal influenza is not on the national immunization schedule in China and India.
Immunization provides the best protection against the influenza virus and vaccines have been available for decades with a recent switch from trivalent to quadrivalent vaccines that protect against each two influenza type A and two B strains. Traditionally, seasonal influenza vaccines have been produced in eggs, but a slow manufacturing process and viral egg-adaptations have led to a push for cell-based and recombinant vaccine production methods in recent years.
Key Questions Answered
How will the seasonal influenza vaccine market landscape in the 3GM (China, India Japan) change from 2018–2028?
What are the most promising late-stage pipeline products for seasonal influenza vaccination?
How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing immunization options?
What are the remaining unmet needs in seasonal influenza immunization?
What drivers and barriers will affect seasonal influenza vaccine sales in the 3GM over the forecast period?

Scope

Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline Seasonal influenza market revenue from 2018–2028. Annual cost of immunization and major pipeline product sales in this forecast period are included.

Key topics covered include current vaccination options, unmet needs and opportunities, and the drivers and barriers affecting seasonal influenza vaccine sales in the 3GM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the APAC seasonal influenza vaccine market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

During the 10-year forecast period, there are nine pipeline products that are on track to launch, driving a forecast growth in the 3GM from $914M in 2018 to $1.05B in 2028, which represents a CAGR of 1.4%.

The late stage pipeline for seasonal influenza vaccines in the 3GM includes the first quadrivalent seasonal influenza vaccines in China from Sinovac, Chongqing Zhifei, and Wuhan, as well as a quadrivalent formulation of Fluad. Quadrivalent live-attenuated vaccines will launch in India (from the Serum Institute) and Japan (AstraZeneca’s FluMist, licensed by Daiichi Sankyo). Furthermore, two new inactivated quadrivalent vaccines from Biken and Denka Seiken will launch during the forecast period, as well as a novel plant-based influenza vaccine in Japan. Medicago’s MDG-2271 will be the first non-egg-based vaccine to launch in the 3GM, addressing the urgent unmet need of influenza vaccine efficacy by shortening production time and minimizing virus mutations.

Another major unmet need in the 3GM is a high vaccination rate and the lack of government support for seasonal influenza immunization in China and India, resulting in vaccination rates around 2%. Vaccination rates in Japan are projected to remain low due to vaccine hesitancy and skepticism.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the APAC seasonal influenza vaccine market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Cadila
Denka Seiken
Medicago
Mitsubishi Tanabe
Sanofi
Seqirus
Serum Institute of India
Sinovac
Takeda

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Seasonal Influenza Vaccines: Executive Summary

2.1 Modest Growth Expected for the Seasonal Influenza Vaccine APAC Market over the Forecast Period from 2018–2028

2.2 Transition from Trivalent to Quadrivalent Influenza Vaccines in China and India, Launch of Specialized Vaccines in Japan

2.3 Higher Seasonal Influenza Vaccination Rates and Better Vaccine Efficacy Are Major Unmet Needs

2.4 Quadrivalent Inactivated and Live-Attenuated Influenza Vaccines Will Launch in China and India, Plant-Based Vaccine in Japan

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.1.3 Symptoms and Prognosis

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 China

5.3.2 India

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Disease Seasonal Influenza (2018–2028)

5.5.1 Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza

5.5.2 Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza

5.5.3 Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza

5.5.4 Lab-Confirmed Seasonal Influenza Mortality

5.5.5 Age-Specific Vaccination of Seasonal Influenza

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management in APAC

6.1 Diagnosis and Treatment Overview

6.2 China

6.3 India

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment in APAC

8.1 Overview

8.2 Immunization Programs Including the Elderly and Children

8.3 Enhanced Vaccine Efficacy in High-Risk Groups

8.4 Public Opinion of Seasonal Influenza Vaccines: Awareness, Hesitancy, and Skepticism

8.5 Vaccines Leveraging Improved Manufacturing Technologies and Featuring Broader Influenza Strain Coverage

9 Pipeline Assessment in APAC

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players in APAC

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessment

10.3.1 Takeda

10.3.2 Denka Seiken

10.3.3 Mitsubishi Tanabe

10.3.4 Sanofi

10.3.5 Seqirus

10.3.6 Serum Institute

10.3.7 Cadila

10.3.8 Sinovac

10.3.9 Medicago

10.3.10 Other Companies

11 Market Outlook in APAC

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 China

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 India

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Vaccine Coverage

12.3.3 Drugs Included in Each Therapeutic Class

12.3.4 Launch Dates

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions

12.3.7 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Seasonal Influenza Vaccines: Key Metrics in the 3GM in APAC

Table 2: Influenza Symptoms

Table 3: Risk Factors and Comorbidities for Seasonal Influenza

Table 4: National Vaccination Recommendations for Seasonal Influenza

Table 5: Main Vaccines and Targeted Population for Routine Administration in China

Table 6: Main Vaccines and Targeted Population for Routine Administration in India

Table 7: Main Vaccines and Targeted Population for Routine Administration in Japan

Table 8: Leading Vaccines for Seasonal Influenza, 2019

Table 9: Takeda’s Disease Portfolio Assessment, 2019

Table 10: Denka Seiken’s Disease Portfolio Assessment, 2019

Table 11: Mitsubishi Tanabe’s Disease Portfolio Assessment, 2019

Table 12: Sanofi’s Disease Portfolio Assessment, 2019

Table 13: Seqirus’ Disease Portfolio Assessment, 2019

Table 14: Serum Institute’s Disease Portfolio Assessment, 2019

Table 15: Cadila’s Disease Portfolio Assessment, 2019

Table 16: Sinovac’s Disease Portfolio Assessment, 2019

Table 17: Medicago’s Disease Portfolio Assessment, 2019

Table 18: Other Companies’ Disease Portfolio Assessment, 2019

Table 19: Seasonal influenza Vaccine Market – Global Drivers and Barriers, 2018–2028

Table 20: Key Events Impacting Sales for Seasonal influenza Vaccines in China, 2018–2028

Table 21: Seasonal Influenza Vaccine Market – Drivers and Barriers in China, 2018–2028

Table 22: Key Events Impacting Sales for Seasonal Influenza Vaccines in India, 2018–2028

Table 23: Seasonal Influenza Vaccines Market – Drivers and Barriers in India, 2018–2028

Table 24: Key Events Impacting Sales for Seasonal Influenza Vaccines in Japan, 2018–2028

Table 25: Seasonal Influenza Vaccines Market – Global Drivers and Barriers in Japan, 2018–2028

Table 26: Key Historical and Projected Launch Dates for Seasonal Influenza Vaccines

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: APAC 3GM Sales Forecast by Country for Seasonal Influenza Vaccines in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in Seasonal Influenza Vaccines During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Prevention of Seasonal Influenza During the Forecast Period

Figure 4: Influenza Virus Structure

Figure 5: Diagnosed Incidence of Lab-Confirmed Seasonal Influenza, Men and Women, All Ages, Cases per 100,000 Population, 2018

Figure 6: 3GM, Sources Used and Not Used for Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza

Figure 7: 3GM, Sources Used for Lab-Confirmed Seasonal Influenza Mortality

Figure 8: 3GM, Sources Used for Proportion of People Receiving Seasonal Influenza Vaccination

Figure 9: 3GM, Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018

Figure 10: 3GM, Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018, N

Figure 11: 3GM, Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, All Ages, 2018, N

Figure 12: 3GM, Lab-Confirmed Seasonal Influenza Mortality, Both Sexes, All Ages, 2018, N

Figure 13: 3GM, Age-Specific Cases of People Receiving Seasonal Influenza Vaccination, Both Sexes, All Ages, 2018, N

Figure 14: Unmet Needs and Opportunities in Seasonal Influenza Vaccination

Figure 15: Overview of the Development Pipeline for Seasonal Influenza Vaccines

Figure 16: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Seasonal Influenza in the 3GM During the Forecast Period

Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Seasonal Influenza Immunization During the Forecast Period

Figure 18: Analysis of the Company Portfolio Gap in Seasonal Influenza Vaccines During the Forecast Period

Figure 19: APAC (3GM) Sales Forecast by Country for Seasonal Influenza Vaccines in 2018 and 2028

Figure 20: Sales Forecast by Class for Seasonal Influenza Vaccines in China in 2018 and 2028

Figure 21: Sales Forecast by Class for Seasonal Influenza Vaccines in India in 2018 and 2028

Figure 22: Sales Forecast by Class for Seasonal Influenza Vaccines in Japan in 2018 and 2028

Frequently asked questions

Seasonal Influenza Vaccines – Forecast in Asia-Pacific Markets to 2028 thematic reports
Currency USD
$8,995

Can be used by individual purchaser only

$26,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Seasonal Influenza Vaccines – Forecast in Asia-Pacific Markets to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Seasonal Influenza Vaccines – Forecast in Asia-Pacific Markets to 2028 in real time.

  • Access a live Seasonal Influenza Vaccines – Forecast in Asia-Pacific Markets to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.